Pharmacy Benefit Spending on Oral Chemotherapy Drugs

Curtiss, Frederic R.

doi:10.18553/jmcp.2006.12.7.570

Cited by 23 publications

(15 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two of the most costly medications in the analysis were erlotinib and imatinib mesylate, with PMPM costs of $0.09 and $0.12. 36 In contrast, the highest PMPM cost estimated for ixabepilone in the present model for any year was $0.006 for years 2 and 3 for populations, were estimated at $64,531, $69,523, and $69,638 for years 1, 2, and 3, respectively. The aggregated AT-p and ATC-p population PMPM costs were determined to be $0.005 for year 1 and $0.006 for years 2 and 3.…”

Section: ■■ Resultscontrasting

confidence: 61%

Budget Impact Analysis of Ixabepilone Used According to FDA Approved Labeling in Treatment-Resistant Metastatic Breast Cancer

Ho¹,

Zhang²,

Todorova³

et al. 2009

JMCP

View full text Add to dashboard Cite

incremental cost PMPM was $0.002 for each of the 3 years. The estimated incremental cost PMPM for the ATC-p population was $0.003 for year 1 and $0.004 for both year 2 and year 3. In sensitivity analyses, the PMPM impact varied between -$0.01 and $0.02 over the 3-year period. The model was most sensitive to the cost of ixabepilone.CONCLUSION: Given the poor prognosis and limited number of treatment options for patients with MBC, the need for widespread coverage of ixabepilone in accordance with FDA-approved indications can clearly be established. Assuming that ixabepilone is used only for its currently labeled indications, both the number of patients eligible for ixabepilone treatment and the expected budget impact of covering ixabepilone for this group of patients are relatively small. ABSTRACT BACKGROUND: Breast cancer is one of the most common forms of cancer in the United States, with approximately 10% of newly diagnosed patients presenting with metastatic disease. Limited therapy options make the successful treatment of metastatic breast cancer (MBC) difficult. Current treatment options include drugs belonging to the classes of anthracyclines and taxanes as well as the drug capecitabine. Resistance to these classes of drugs is often acquired, thus highlighting the need for newer agents capable of managing treatment resistant disease. Ixabepilone is an antineoplastic agent from the epothilone class that was FDA-approved in October 2007 for the treatment of metastatic or locally advanced breast cancer. The FDA-approved indications for ixabepilone specify (a) use of ixabepilone in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer after (resistance to) treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated; and (b) ixabepilone as a monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to an anthracycline, a taxane, and capecitabine.

show abstract

Section: ■■ Resultscontrasting

confidence: 61%

Budget Impact Analysis of Ixabepilone Used According to FDA Approved Labeling in Treatment-Resistant Metastatic Breast Cancer

Ho¹,

Zhang²,

Todorova³

et al. 2009

JMCP

View full text Add to dashboard Cite

show abstract

“…SuMMAry: CML is caused by thetranslocation of chromosomes9and 22 to create what is called thePhiladelphia chromosome. This translocation removesacritical regulatorydomainfromthe tyrosine kinase,ABL,such that itsprotein productisconstitutivelyactive.…”

Section: Chronicmyeloid Leukemia In 2007mentioning

confidence: 99%

“…If onel ooks at theb reakdown of oral chemotherapy from costsr eported from 1h ealth care system, imatiniba ccountedf or 29%o fc lai ms in 2006 ( Figure). 22 This wasactuallyenoughfor this health care system to actually triple itsper-member-per monthpayment plan.Thus, thesedrugs can be extremelyo verwhelmingi nt he overall insurances cheme, especiallyfor smallinsurers or self-insurers.…”

Section: ■■ Economicsoftreatingcmlmentioning

confidence: 99%

Optimizing Outcomes Through Pharmaceutical Advances in the Treatment of Chronic Myeloid Leukemia

Frame¹,

Fausel²,

Sessions³

2007

JMCP

View full text Add to dashboard Cite

“…[10][11][12][13][14] In addition to the enormous cost, these medications have many significant adverse reactions and drug-drug or drug-food interactions, which can directly affect patient safety, adherence, and treatment success. 5,[14][15][16][17] Additionally, some dosing regimens are complicated, and patients can become confused about dosing instructions when these highrisk prescriptions are filled at pharmacies (such as mail-order facilities) where there is no face-to-face relationship with a pharmacist. 5,18 Medication therapy management (MTM), a personalized, unique, one-on-one clinical service offered by a pharmacist, may play a critical role in helping facilitate the safe and effective use of oral antineoplastic agents.…”

mentioning

confidence: 99%

Medication Therapy Management for Patients Receiving Oral Chemotherapy Agents at a Community Oncology Center: A Pilot Study

et al. 2016

View full text Add to dashboard Cite

Purpose:To determine the impact of a pharmacist-driven medication therapy management (MTM) program for patients receiving oral chemotherapy agents. Methods:We assessed the impact of MTM consultations with a pharmacist for patients who were receiving a new prescription for an oral chemotherapy agent. Data were assessed for outcomes including (1) number of medication errors identified in electronic medical records (EMRs), (2) number of interventions performed by the pharmacist, (3) time spent on the MTM process, and (4) patient satisfaction. Data were compared between patients who received their oral chemotherapy agents from the onsite specialty pharmacy or from a mail-order pharmacy. The data were also examined for correlations, and logistic regression was utilized to determine the largest variant cofactor to create an equation for estimating the number of errors in a patient's EMR. Results: Fifteen patients received an MTM consultation, and the pharmacists identified an average of 6 medication EMR errors per patient. There was an average of 3 pharmacist-led interventions per patient. Multiple significant correlations were noted between the variables: (1) total number of prescriptions a patient was taking, (2) total number of medication errors identified, (3) time spent on the MTM process, and (4) total number of interventions performed by the pharmacist. Patient satisfaction was favorable for the program. Conclusion:The implementation of a pharmacist-driven MTM program for patients receiving a prescription for an oral chemotherapy agent had a significant impact on patient care by improving medication reconciliation, identifying drug-related problems, and strengthening pharmacistpatient interactions in the oncology clinic.

show abstract

Pharmacy Benefit Spending on Oral Chemotherapy Drugs

Cited by 23 publications

References 7 publications

Budget Impact Analysis of Ixabepilone Used According to FDA Approved Labeling in Treatment-Resistant Metastatic Breast Cancer

Budget Impact Analysis of Ixabepilone Used According to FDA Approved Labeling in Treatment-Resistant Metastatic Breast Cancer

Optimizing Outcomes Through Pharmaceutical Advances in the Treatment of Chronic Myeloid Leukemia

Medication Therapy Management for Patients Receiving Oral Chemotherapy Agents at a Community Oncology Center: A Pilot Study

Contact Info

Product

Resources

About